Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
|
|
Oncocyte Corp (OCX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/10/2023 |
8-K/A
| Quarterly results |
| 10/05/2023 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits Interactive Data |
| 08/10/2023 |
8-K
| Quarterly results |
| 07/24/2023 |
8-K
| Quarterly results |
| 07/14/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDMENT , is entered into effective July 13, 2023 by and between Oncocyte Corporation , a California corporation located at 15 Cushing, Irvine, California 92618 and Joshua Riggs . WHEREAS, the Company and Executive previously entered into that certain Amended and Restated Employment Agreement, effective May 1, 2023 ; WHEREAS, pursuant to Section 12 of the Employment Agreement, the Employment Agreement may be amended, in writing, signed by both the Company and Executive; WHEREAS, the Company and Executive desire to amend the Employment Agreement as set forth herein; and WHEREAS, capitalized terms not otherwise defined in this Amendment shall have the meanings ascribed to such terms in the Employment Agreement. NOW, THEREFORE, in ..." |
|
| 06/29/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 06/08/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/06/2023 |
8-K
| Investor presentation |
| 05/11/2023 |
8-K
| Quarterly results |
| 04/13/2023 |
8-K
| Quarterly results |
| 04/05/2023 |
8-K
| Results of Operations and Financial Condition, Other Events Interactive Data |
| 03/31/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 03/02/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/23/2023 |
8-K
| Asset disposition|
Docs:
|
"Second AMENDMENT TO STOCK PURCHASE AGREEMENT THIS SECOND AMENDMENT TO STOCK PURCHASE AGREEMENT is adopted as of the 16th day of February, 2023 , by and among Oncocyte Corporation, a California corporation , Dragon Scientific, LLC, a Delaware limited liability company , and Razor Genomics, Inc., a Delaware corporation . Seller, Company, and Buyer are referred to herein individually as a “Party” and collectively as the “Parties.” Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Stock Purchase Agreement . WHEREAS, Buyer, Seller and the Company have entered into that certain Stock Purchase Agreement, dated as of December 15, 2022 and amended the same pursuant to that certain First Amendment to Stock Purchase Agreement entered into as...",
"ONCOCYTE CORPORATION UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION On February 16, 2023, Oncocyte Corporation completed its sale of 3,188,181 shares of common stock of its wholly-owned subsidiary Razor Genomics, Inc. , which constitutes approximately 70% of the issued and outstanding equity interests of Razor on a fully-diluted basis, pursuant to a previously announced Stock Purchase Agreement with Dragon Scientific, LLC, a Delaware limited liability company , and Razor, a Delaware corporation . In connection with the Closing, Oncocyte transferred to Razor all of the assets and liabilities related to DetermaRx TM , a test used to predict a patient’ s risk of cancer recurrence following surgery and response to chemotherapy in early-stage lung cancer. Following the Closing...",
"ONCOCYTE COMPLETES RAZOR GENOMICS TRANSACTION" |
|
| 02/13/2023 |
8-K
| Quarterly results |
| 02/03/2023 |
8-K
| Quarterly results |
| 01/30/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and... |
| 12/21/2022 |
8-K
| Quarterly results |
| 12/05/2022 |
8-K
| Quarterly results |
| 11/23/2022 |
8-K
| Quarterly results |
| 11/10/2022 |
8-K
| Quarterly results |
| 11/09/2022 |
8-K
| Quarterly results |
| 09/26/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/15/2022 |
8-K
| Quarterly results |
| 08/10/2022 |
8-K
| Quarterly results |
| 08/03/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/01/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/21/2022 |
8-K
| Quarterly results |
| 07/15/2022 |
8-K
| Quarterly results |
| 06/30/2022 |
8-K
| Quarterly results |
| 05/11/2022 |
8-K
| Quarterly results |
| 04/19/2022 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"26,266,417 SHARES of Common Stock and 26,266,417 Warrants TO PURCHASE 13,133,208.5 SHARES OF COMMON STOCK of ONCOCYTE CORPORATION UNDERWRITING AGREEMENT April 13, 2022 BTIG, LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto c/o BTIG, LLC 600 Montgomery Street, 6th Floor San Francisco, California 94111",
"COMMON STOCK PURCHASE WARRANT oncocyte corporation Warrant Shares: [●] Initial Exercise Date: April 19, 2022 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, [_____________] or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and on or prior to 5:00 p.m. on April 19, 2027 but not thereafter, to subscribe for and purchase from Oncocyte Corporation, a California corporation , up to [●] shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . In addition to the terms defined elsewhere in this Warrant, the following terms hav...",
"Re: Registration Statement of Oncocyte Corporation",
"ONCOCYTE CORPORATION ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND WARRANTS",
"ONCOCYTE CORPORATION ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK AND WARRANTS" |
|
| 04/13/2022 |
8-K
| Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other E...|
Docs:
|
"CERTIFICATE OF DETERMINATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES a CONVERTIBLE PREFERRED STOCK OF Oncocyte corporatiOn The undersigned, Ronald S. Andrews and Peter Hong, do hereby certify that: I. They are the President and Secretary, respectively, of Oncocyte Corporation, a California corporation with Entity Number 3231738. II. The following resolutions were duly adopted by the board of directors of the Corporation pursuant to authority given by the corporation’ s Articles of Incorporation: “RESOLVED, that pursuant to the authority vested in the board of directors of the Corporation by Article FOUR of the Corporation’ s Articles of Incorporation, a series of Preferred Stock of the Corporation is created out of the authorized but unissued shares of Preferred Stock of the Corpo...",
"Re: Registration Statement of Oncocyte Corporation",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of April ___, 2022, between Oncocyte Corporation, a California corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act , the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and each Purchase...",
"Investor Contact" |
|
| 03/14/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
|
|
|